Drug intelligence / Profile preview

mitomycin C + vindesine

Development stage
Unknown
Modality
Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

Mitomycin C + vindesine is a combination chemotherapy regimen consisting of two antineoplastic agents, mitomycin C and vindesine. Mitomycin C is an alkylating agent that acts as an antitumor antibiotic by cross-linking DNA strands, thereby inhibiting DNA synthesis and leading to cell death. Vindesine is a vinca alkaloid that inhibits microtubule formation in the mitotic spindle, preventing cell division during metaphase. This combination has been studied for use in advanced cancers such as breast cancer and non-small-cell lung cancer (NSCLC), often as part of multi-drug regimens or in patients with refractory disease[2][3]. The primary mechanism of action involves disruption of DNA replication (mitomycin C) and inhibition of microtubule assembly (vindesine), resulting in cytotoxic effects on rapidly dividing tumor cells.

Other names
mitomycin C and vindesinemitomycin plus vindesine
02

Targets

DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on mitomycin C + vindesine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mitomycin C + vindesine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call